Clinical Trial Update: Immunogenicity, Safety, and Tolerability of rF1V-1018 Vaccine in Adults 18 to 55 Years of Age [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the immunogenicity, safety, and tolerability of the rF1V-1018 vaccine in adults 18-55 for pneumonic plague prevention; the stu…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumonic Plague

Drugs mentioned

• rF1V-1018 vaccine

Snippet

Sponsor: Dynavax Technologies Corporation | Conditions: Prevention of Pneumonic Plague Resulting From Aerosol Exposure to Yersenia Pestis | Phase 2 | Status: RECRUITING